Urology
Volume 57, Issue 4, Supplement 1 , Pages 56-63 , April 2001

Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents

  • William G Nelson

      Affiliations

    • Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • Department of Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (WGN)
    • Corresponding Author InformationReprint requests: William G. Nelson, MD, PhD, Marburg 411, The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287
    • ,
  • George Wilding

      Affiliations

    • Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA (GW)

References 

  1. Carter BS, Carter HB, Isaacs JT. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate. 1990;16:187–197
  2. Cancer incidence in five continents. Volume VII. IARC Sci Publ 143: 1–1240, 1997.
  3. Shimizu H, Ross RK, Bernstein L, et al.  Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. 1991;63:963–966
  4. Lee MM, Wang RT, Hsing AW, et al.  Case-control study of diet and prostate cancer in China. Cancer Causes Control. 1998;9:545–552[see comments]
  5. Kolonel LN, Yoshizawa CN, Hankin JH. Diet and prostatic cancer (a case-control study in Hawaii). Am J Epidemiol. 1988;127:999–1012
  6. Giovannucci E, Rimm EB, Colditz GA, et al.  A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993;85:1571–1579[see comments]
  7. Sakr WA, Grignon DJ, Crissman JD, et al.  High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69 (an autopsy study of 249 cases). In Vivo. 1994;8:439–443
  8. Yoshizawa K, Willett WC, Morris SJ, et al.  Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst. 1998;90:1219–1224[see comments]
  9. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer (review of the epidemiologic literature). J Natl Cancer Inst. 1999;91:317–331
  10. Strom SS, Yamamura Y, Duphorne CM, et al.  Phytoestrogen intake and prostate cancer (a case-control study using a new database). Nutr Cancer. 1999;33:20–25
  11. Isaacs WB. Molecular genetics of prostate cancer. Cancer Surv. 1995;25:357–379
  12. Dong JT, Isaacs WB, Isaacs JT. Molecular advances in prostate cancer. Curr Opin Oncol. 1997;9:101–107
  13. Collins FS. The human genome project and the future of medicine. Ann N Y Acad Sci. 1999;882:42–65
  14. Kuska B. Cancer genome anatomy project set for take-off. J Natl Cancer Inst. 1996;88:1801–1803[news]
  15. Clark LC, Dalkin B, Krongrad A, et al.  Decreased incidence of prostate cancer with selenium supplementation (results of a double-blind cancer prevention trial). Br J Urol. 1998;81:730–734
  16. Andriole G, Lieber M, Smith J, et al.  Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 1995;45:491–497
  17. Presti JC, Fair WR, Andriole G, et al.  Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol. 1992;148:1201–1204
  18. Feigl P, Blumenstein B, Thompson I, et al.  Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials. 1995;16:150–163
  19. Hsieh TC, Wu JM. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression. Prostate. 1997;33:97–104
  20. Roberson KM, Penland SN, Padilla GM, et al.  Fenretinide (induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells). Cell Growth Differ. 1997;8:101–111
  21. Dahiya R, Park HD, Cusick J, et al.  Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer. 1994;59:126–132
  22. Igawa M, Tanabe T, Chodak GW, et al.  N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells. Prostate. 1994;24:299–305
  23. de Vos S, Dawson MI, Holden S, et al.  Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells. Prostate. 1997;32:115–121
  24. Blutt SE, Allegretto EA, Pike JW, et al.  1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology. 1997;138:1491–1497
  25. Hong WK, Lippman SM, Itri LM, et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990;323:795–801[see comments]
  26. Hedlund TE, Moffatt KA, Uskokovic MR, et al.  Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res. 1997;3:1331–1338
  27. Wang X, Chen X, Akhter J, et al.  The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3). Br J Urol. 1997;80:260–262
  28. Campbell MJ, Elstner E, Holden S, et al.  Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol. 1997;19:15–27
  29. Schwartz GG, Hill CC, Oeler TA, et al.  1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology. 1995;46:365–369
  30. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer (1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines). Endocrinology. 1993;132:1952–1960
  31. Kohl NE, Omer CA, Conner MW, et al.  Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med. 1995;1:792–797[see comments]
  32. Casey PJ, Solski PA, Der CJ, et al.  p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA. 1989;86:8323–8327
  33. Reiss Y, Goldstein JL, Seabra MC, et al.  Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell. 1990;62:81–88
  34. Ohguro H, Fukada Y, Takao T, et al.  Carboxyl methylation and farnesylation of transducin gamma-subunit synergistically enhance its coupling with metarhodopsin II. Embo J. 1991;10:3669–3674
  35. Anant JS, Fung BK. In vivo farnesylation of rat rhodopsin kinase. Biochem Biophys Res Commun. 1992;183:468–473
  36. Anant JS, Ong OC, Xie HY, et al.  In vivo differential prenylation of retinal cyclic GMP phosphodiesterase catalytic subunits. J Biol Chem. 1992;267:687–690
  37. Whyte DB, Kirschmeier P, Hockenberry TN, et al.  K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997;272:14459–14464
  38. Akiyama T, Ishida J, Nakagawa S, et al.  Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592–5595
  39. Oshima M, Dinchuk JE, Kargman SL, et al.  Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803–809
  40. Sano H, Kawahito Y, Wilder RL, et al.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995;55:3785–3789
  41. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer. 1997;75:1111–1118
  42. Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA. 1998;95:13182–13187
  43. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth (critical role of 5-lipoxygenase). Biochem Biophys Res Commun. 1997;235:418–423
  44. Anderson KM, Harris JE. 5,8,11,14-eicosatetraynoic acid inhibits PC3 DNA synthesis and cellular proliferation, in part due to its 5′-lipoxygenase activity. Clin Physiol Biochem. 1990;8:308–313
  45. Hwang LC, Fein S, Levitsky H, et al.  Prostate cancer vaccines (current status). Semin Oncol. 1999;26:192–201
  46. Nelson JB, Chan-Tack K, Hedican SP, et al.  Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996;56:663–668
  47. Nelson JB, Hedican SP, George DJ, et al.  Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944–949
  48. Steward WP. Marimastat (BB2516) (current status of development). Cancer Chemother Pharmacol. 1999;43:S56–S60
  49. Powell WC, Knox JD, Navre M, et al.  Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res. 1993;53:417–422
  50. Sehgal G, Hua J, Bernhard EJ, et al.  Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol. 1998;152:591–596
  51. Chan JM, Stampfer MJ, Giovannucci E, et al.  Plasma insulin-like growth factor-I and prostate cancer risk (a prospective study). Science. 1998;279:563–566[see comments]
  52. Cohen P, Peehl DM, Graves HC, et al.  Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol. 1994;142:407–415
  53. Kennedy AR. Prevention of carcinogenesis by protease inhibitors. Cancer Res. 1994;54:1999s–2005s
  54. Kristal AR, Stanford JL, Cohen JH, et al.  Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:887–892
  55. Heinonen OP, Albanes D, Virtamo J, et al.  Prostate cancer and supplementation with alpha-tocopherol and beta-carotene (incidence and mortality in a controlled trial). J Natl Cancer Inst. 1998;90:440–446[see comments]
  56. Ripple MO, Henry WF, Rago RP, et al.  Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst. 1997;89:40–48[see comments]
  57. Ripple MO, Henry WF, Schwarze SR, et al.  Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst. 1999;91:1227–1232
  58. De Marzo AM, Coffey DS, Nelson WG. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology. 1999;53:29–42
  59. De Marzo AM, Marchi VL, Epstein JI, et al.  Proliferative inflammatory atrophy of the prostate (implications for prostatic carcinogenesis). Am J Pathol. 1999;155:1985–1992

PII: S0090-4295(00)00942-0

Urology
Volume 57, Issue 4, Supplement 1 , Pages 56-63 , April 2001

Article Tools